Most American investors are familiar with large European drug companies like Sanofi and Novartis (NVS), but the mid-cap drugmakers like Ipsen (OTCPK:IPSEY) don't get as much attention. That's unfortunate, as Ipsen is one of several high-quality smaller European pharmaceutical companies.
Ipsen shares don't look significantly underpriced today, but there could some developments that could drive shares higher. Phase III data on tasquinimod could make this drug a viable alternative in the crowded prostate cancer space, and Ipsen may be on the prowl for licensing or acquisition opportunities to take advantage of a new U.S. oncology sales infrastructure. I'd more interested in these shares closer to EUR 30, but they look like a decent...
Only subscribers can access this article, which is part of the PRO research library covering 3,555 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: